Amg 2024 Hbv. In two initial v8 flavors, both. If that’s a little too much to handle, there is a.

Current evidence suggests a single therapeutic agent alone may be insufficient, necessitating the need for combination therapy targeting hbv and the host immune response. Amg reports financial and operating results for the first quarter of 2024.